Browsing by Author "Abbattista, M"

Now showing items 1-4 of 4

Title: Development of CP506 a novel hypoxia-selective cytotoxin for the treatment of triple negative breast cancer (TNBC) Author: Moore, Sarah Date: (2019)
Title: EP-2327: Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrug Author: Niemans, R ; Yaromina, A ; Theys, J ; Marcus, D ; Ashoorzadeh, Amir ; Abbattista, M ; Mowday, A ; Biemans, R ; Lieuwes, N ; Deschoemaeker, S ; Heyerick, A ; Guise, C ; Smaill, Jeffrey ; Patterson, Adam ; Dubois, L ; Lambin, P Date: (2018-04)
Title: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966 Author: Smaill, Jeffrey ; Jaiswal, Jagdish ; Abbattista, M ; Lu, Guo-Liang ; Anderson, BF ; Ashoorzadeh, Amir ; Denny, William ; Donate, F ; Hsu, HL ; Lee, HH ; Maroz, A ; mehta, S ; Pruijn, A ; Puryer, M ; Syddall, SP ; Thompson, A ; van Leeuwen, W ; Wilson, WR ; Jamieson, S ; Patterson, AV Reference: AACR-NCI-EORTC International Conference:Molecular Targets and Cancer Therapeutics. 06 Nov 2011
Title: Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). Author: Jackson, V ; Silva, S ; Abbattista, M ; Guise, Christopher ; Bull, M ; Ashoorzadeh, A ; Hart, C ; Pearce, T ; Smaill, Jeffrey ; Patterson, Adam Reference: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2015

Now showing items 1-4 of 4

Search ResearchSpace

Browse

All of ResearchSpace